Achillion Pharmaceuticals, Inc.
|Number of Estimates|
Achillion Pharmaceuticals, Inc. engages in the discovery and development of small molecule drug therapies for immune system disorders. It offers its propriety platform of potent and specific complement factor D inhibitors for AP-mediated diseases. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.
Market Cap: 864 Million
Primary Exchange: NASDAQ
Shares Outstanding: 140 Million
Float: 136 Million
Sector: Health Technology
Longest drawdown: 1244 trading days
From: 2015-01-23 To: 2019-12-04
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|